Human Oncology & Pathogenesis Program

The Ivan Maillard Lab

Research

Dr. Ivan Maillard
Ivan Maillard, MD, PhD

Dr. Maillard’s research focuses on the role of Notch signaling in hematopoiesis as well as in T and B cell development, differentiation and function. Through more than 15 years of research in the field, his laboratory discovered essential functions for Notch receptors and ligands in graft-versus-host disease with a high fundamental and translational impact. His work also identified specialized stromal niches that represent the critical sources of Notch ligands in secondary lymphoid organs, sparking a new interest in the biology of lymphoid tissue fibroblastic reticular cells in immune and hematologic disorders. Ongoing projects in the laboratory build on these discoveries to explore the role of Notch signaling in immune cell function and malignant transformation.

Research Projects

  • Notch signaling in alloimmunity
  • Notch signaling in anti-cancer immunity
  • Role of Notch in T follicular helper responses
  • Oncogenic Notch signals in T-cell lymphomas
  • Immunobiology of lymph node fibroblastic reticular cells

Publications Highlights

Zhang Y, Sandy AR, Wang J, Shan GT, Radojcic V, Tran I, Friedman A, Kato K, He S, Cui S, Hexner E, Frank D, Emerson SG, Pear WS, Maillard I. Notch signaling is a critical regulator of allogeneic CD4+ T cell responses mediating graft-versus-host disease. Blood, 117(1): 299-308, 2011. PMCID: PMC3037751

Tran IT, Sandy AR, Carulli AJ, Ebens C, Chung J, Shan GT, Radojcic V, Friedman A, Gridley T, Shelton A, Reddy P, Samuelson LC, Yan M, Siebel CW, Maillard I. Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J Clin Invest, 123(4): 1590-1604, 2013. PMCID: PMC3613915

Chung J, Ebens CE, Perkey E, Radojcic V, Koch U, (…), Friedman A, Granadier D, Tran IT, Chai Q, Onder L, Yan M, Reddy P, Blazar BR, Huang AY, Brennan TV, Bishop DK, Ludewig B, Siebel CW, Radtke F, Luther SA, Maillard I. Fibroblastic niches prime T cell alloimmunity through Delta-like Notch ligands. J Clin Invest, 127(4): 1574-88, 2017. PMCID: PMC5373885

Gómez Atria D*, Gaudette BT*, Londregan J*, Kelly S, Perkey E, Allman A, Srivastava B, Koch U, Radtke F, Ludewig B, Siebel CW, Ryan RJH, Robertson TF, Burkhardt JK, Pear WS, Allman D**, Maillard I**. Stromal Notch ligands foster lymphopenia-driven functional plasticity and homeostatic proliferation of naïve B cells. J Clin Invest, 2022 Jul 1;132(13):e158885. doi: 10.1172/JCI158885. PMCID: PMC9246379.

Tkachev V*, Vanderbeck A*, Perkey E*, Furlan SN, McGuckin C, Gómez Atria D, Gerdemann U, Rui X, Lane J, Hunt DJ, Zheng H, Colonna L, Hoffman M, Yu A, Outen R, Kelly S, Allman A, Burbach B, Shimizu Y, Panoskaltsis-Mortari, Chen G, Carpenter SM, Harari O, Kuhnert F, Thurston G, Blazar BR, Kean LS**, Maillard I**. Notch signaling drives intestinal graft-versus-host disease in mice and non-human primates. Science Translational Medicine15(702):eadd175, 2023. PMID: 37379368.

View All Publications

People

Dr. Ivan Maillard

Ivan Maillard, MD, PhD

  • New roles for Notch signaling in the immune system.
maillai@mskcc.org
Email Address

Members

Ellen Cangialosi
Lab Administrative Assistant
Kanaka Dhuri
Research Technician
Oriana Miltiadous
Instructor, Pediatrics
Jianmin Yang
Lab Manager
Yunlin Zhang
GSK Graduate Rotation Student

Achievements

  • Member, Association of American Physicians (2024)
  • Interurban Clinical Club (2019)
  • DuPont Guerry, IV, MD Award for Outstanding Mentorship, University of Pennsylvania Perelman School of Medicine (2019)
  • League of Research Excellence, University of Michigan Medical School (2014)
  • Member, American Society of Clinical Investigation (2013)

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Get in Touch

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Ivan Maillard discloses the following relationships and financial interests:

  • Garuda Therapeutics
    Professional Services and Activities
  • Sanofi US Services Inc.
    Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures